CONTEXT: Renal cell carcinoma is a heterogeneous group of tumors with distinct histopathologic features, molecular characteristics, and clinical outcome. These tumors can be sporadic as well as familial or associated with syndromes. The genetic abnormalities underlying these syndromes have been identified and were subsequently found in corresponding sporadic renal tumors. OBJECTIVE: To review the recent molecular and genetic advancements relating to sporadic and familial renal carcinomas as well as those related to Xp11.2 translocation-associated renal cell carcinoma and renal medullary carcinoma. DATA SOURCES: Literature review, personal experience, and material from the University of Chicago. CONCLUSIONS: Molecular genetic diagnostic techniques will continue to introduce new biomarkers that will aid in the differential diagnosis of difficult cases. The identification of specific signaling pathways that are defective in certain renal tumors also makes possible the development of new therapies that selectively target the aberrant activity of the defective proteins.
CONTEXT: Renal cell carcinoma is a heterogeneous group of tumors with distinct histopathologic features, molecular characteristics, and clinical outcome. These tumors can be sporadic as well as familial or associated with syndromes. The genetic abnormalities underlying these syndromes have been identified and were subsequently found in corresponding sporadic renal tumors. OBJECTIVE: To review the recent molecular and genetic advancements relating to sporadic and familial renal carcinomas as well as those related to Xp11.2 translocation-associated renal cell carcinoma and renal medullary carcinoma. DATA SOURCES: Literature review, personal experience, and material from the University of Chicago. CONCLUSIONS: Molecular genetic diagnostic techniques will continue to introduce new biomarkers that will aid in the differential diagnosis of difficult cases. The identification of specific signaling pathways that are defective in certain renal tumors also makes possible the development of new therapies that selectively target the aberrant activity of the defective proteins.
Authors: Simon Chowdhury; Marc R Matrana; Christopher Tsang; Bradley Atkinson; Toni K Choueiri; Nizar M Tannir Journal: Hematol Oncol Clin North Am Date: 2011-08 Impact factor: 3.722
Authors: Peter H O'Donnell; Ana Jensen; Edwin M Posadas; Julia A Bridge; Anjana V Yeldandi; Ximing J Yang; Walter M Stadler; Hikmat Al-Ahmadie Journal: Nat Rev Urol Date: 2010-02 Impact factor: 14.432
Authors: Ondrej Slaby; Jana Jancovicova; Radek Lakomy; Marek Svoboda; Alexandr Poprach; Pavel Fabian; Leos Kren; Jaroslav Michalek; Rostislav Vyzula Journal: J Exp Clin Cancer Res Date: 2010-07-07